Author： Appell Rodney A
Publisher： Future Medicine
ISSN： 1745-5057
Source： Women's Health, Vol.2, Iss.2, 2006-03, pp. : 225-230
Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.
Abstract
It has long been accepted that antimuscarinic agents are the backbone of the pharmacological treatment of overactive bladder. Oxybutynin has been the gold standard of these medications for years due to its efficacy, but suffers from a lack of selectivity for the bladder, and extensive metabolism and lipophilicity result in significant side-effect issues. The transdermal delivery of oxybutynin turns this disadvantage of lipophilicity into an advantage. This, in turn, bypasses gastrointestinal absorption and metabolism by the cytochrome P450 system and reduces the breakdown into metabolites responsible for many of the side effects, while providing equivalent efficacy to the immediate-release oral formulation.
Related content
By Hart Warren Mark Abrams Paul Munro Vicki Retsa Peny Nazir Jameel
Journal of Medical Economics, Vol. 16, Iss. 10, 2013-10 ,pp. :
Access to resources
Recommend
Solifenacin for the treatment of overactive bladder
By Robinson Dudley Cardozo Linda
Therapy, Vol. 8, Iss. 6, 2011-11 ,pp. :
Overactive bladder: diagnosis and treatment
By Vij Monika Robinson Dudley Cardozo Linda
Women's Health, Vol. 6, Iss. 2, 2010-03 ,pp. :
By Teng Lesheng Jiang Chaojun Sun Fengying Li Chunmei Teng Lirong Meng Qingfan Lee Robert J. Li Youxin
Journal of Microencapsulation, Vol. 30, Iss. 2, 2013-03 ,pp. :